Advancements in Heart Failure

Videos

Advancements in Heart Failure

The prevalence of heart failure (HF) continues to increase over time1 and affects >60 million people each year2.

Therefore, being aware of the latest data in the HF space and different treatment options is important in order to be able to apply findings to clinical practice when making treatment decisions for patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease, especially HF.

This section is supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company Alliance

Boehringer Ingelheim

Content on this section was partly provided by Boehringer Ingelheim. For any follow up questions please contact your local Boehringer Ingelheim representative.

Most Popular

Review articles

Pages

Systematic Analysis

Pages

Guidelines

Pages

Clinical Case Study

Pages

Study Design

Pages

1.Heart disease and stroke statistics-2020 update: a report from the American Heart Association

Virani SS, Alonso A, Benjamin EJ, et al. Circulation 2020;141:e139-e596.

https://doi.org/10.1161/CIR.0000000000000757

2. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Lancet 2017;390:1211-59.

https://doi.org/10.1016/S0140-6736(17)32154-2

Advances in Heart Failure: A Year of Discovery - Moving Forward with SGLT-2 Inhibitors

PART 1: SGLT-2 inhibitors: Where Are We Now?

Learning objectives

  • Evaluate emerging data on the treatment of heart failure with SGLT2 inhibitors in patients with or without T2DM
  • Interpret the new data on the treatment of heart failure with SGLT2 inhibitors in patients with or without T2DM in relationship to the existing data.
  • Understand the implementation of the emerging data on the treatment of heart failure with SGLT2 inhibitors in patients with or without T2DM for clinical practice.

 


Programme Outline
  • PART 1: SGLT-2 inhibitors: Where Are We Now?Andrew JS CoatsHarriette Van SpallFaiez Zannad
  • PART 2: SGLT2 Inhibitors in HFrEF: EMPEROR-ReducedAndrew JS CoatsHarriette Van SpallFaiez Zannad
  • PART 3: SGLT-2 Inhibitors in ContextAndrew JS CoatsHarriette Van SpallFaiez Zannad
Supported by an unrestricted educational service from Boehringer Ingelheim

PART 2: SGLT2 Inhibitors in HFrEF: EMPEROR-Reduced

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition

Creative Commons Licence
 
Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Heart failure (HF) is a complex syndrome caused by functional and structural abnormalities of the left ventricle (LV) resulting in a combination of typical signs and symptoms.

Advances in Heart Failure - Is it Time to Redefine Patient Selection for Sodium-glucose co-transporter 2 Inhibitors?

PART 1: SGLT2s as a Heart Failure Drug – How Did We Get Here?

Learning objectives

  • Discuss current SGLT2 data and guideline recommendations for utilization in heart failure
  • Evaluate emerging data on the treatment of heart failure with SGLT2 inhibitors
  • Understand the implications of emerging data on the treatment of heart failure with SGLT2 inhibitors for clinical practice.
Martin R Cowie
National Heart and Lung Institute, Imperial College and Royal Brompton Hospital, London

 


Programme Outline
  • PART 1: SGLT2s as a Heart Failure Drug – How Did We Get Here?Martin R Cowie
  • PART 2: Emerging Data SGLT2 Inhibitors in Heart FailureFaiez Zannad
  • PART 3: Guidelines and Practice ImplicationsSanjay Kaul
  • PART 4: Q&A DiscussionMartin R CowieFaiez ZannadSanjay Kaul
  • PART 5: Follow-up Peer-to Peer DiscussionAndrew JS CoatsFaiez Zannad
This independent medical education symposium was supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company alliance.

PART 2: Emerging Data SGLT2 Inhibitors in Heart Failure

Malaysia in Focus - ARNI Data and its Implications on Clinical Practice

PART 1: Meet the Expert Presentation – Local Interpretation of Emerging ARNI Data in HF

 


Programme Outline
  • PART 1: Meet the Expert Presentation – Local Interpretation of Emerging ARNI Data in HFCarolyn LamWan Azman Wan Ahmad
  • PART 2: Meet the Expert Q&A – Local Interpretation of Emerging ARNI Data in HFCarolyn LamWan Azman Wan Ahmad
  • PART 3: Interview - Managing Hypotension in Patients with HFrEF (Utilising ARNIs)Carolyn Lam
  • PART 4: Clinical questions on ARNI therapy - Chapter 1: Local Interpretation of Emerging ARNI Data in HFAzmee Modh Ghazi
  • PART 4: Clinical questions on ARNI therapy - Chapter 2: ARNI Therapy Mode of ActionAzmee Modh GhaziJames L JanuzziAkshay S Desai
  • PART 4: Clinical questions on ARNI therapy - Chapter 3: Safety and Efficacy of ARNI Therapy in Acute Heart FailureAzmee Modh GhaziDavid Morrow
  • PART 4: Clinical questions on ARNI therapy - Chapter 4: When to Initiate ARNI Therapy in Acute Heart FailureAzmee Modh GhaziRolf Wachter
  • PART 4: Clinical questions on ARNI therapy - Chapter 5: SummaryAzmee Modh Ghazi
This programme was supported by an unrestricted educational grant from Novartis.

PART 2: Meet the Expert Q&A – Local Interpretation of Emerging ARNI Data in HF

Time to Take the Lead – Practical Utilization of SGLT2 Inhibitors

PART 1: Introduction, and No Permission Needed – Cardiology Guidelines + Prescribing Practice

Learning objectives

  • Understand current guidelines and utilisation of SGLT2i
  • Describe the potential mechanism of benefit of SGLT2i
  • Initiate and manage SGLT2i in appropriate patients

 


Programme Outline
  • PART 1: Introduction, and No Permission Needed – Cardiology Guidelines + Prescribing PracticeJaved ButlerShelley Zieroth
  • PART 2: SGLT2i are Cardiovascular DrugsJaved Butler
  • PART 3: Cardiologists Taking the Lead – How Can We Use SGLT2 Inhibitors in Our Clinical Practice?Stefan Anker
  • PART 4: Case DiscussionJaved ButlerShelley ZierothStefan Anker
  • PART 5: A Follow-up Discussion to the ESC 2020 SessionJaved ButlerShelley Zieroth
This independent medical education symposium was supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company alliance.

PART 2: SGLT2i are Cardiovascular Drugs

Pages

Subscribe to RSS - Advancements in Heart Failure